Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced NSCLC
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 Dec 2019 Results evaluating the potential effect of dacomitinib in patients with advanced non-small cell lung cancer enrolled were published in the Investigational New Drugs
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 16 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.